Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Blood Sampling For High Molecular Weight Dna Extraction

Research Leaders

5 sponsors active, led by Centre Hospitalier Universitaire Dijon

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00140829CompletedPrimary

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

NCT06467175Not ApplicableRecruitingPrimary

The Benefits of Long-read High-throughput Genomic Sequencing for the Causal Diagnosis of Cerebellar Ataxias

Showing all 2 trials

Research Network

Common Treatments

  • Blood Sampling For High Molecular Weight Dna Extraction1

Active Sponsors

  • Centre Hospitalier Universitaire Dijon1
  • Institut des Maladies Rares1
  • Institut National de la Santé Et de la Recherche Médicale, France1
  • National Research Agency, France1
  • Paris Brain Institute (ICM)1

Top Investigators

Related Conditions

  • Spastic Paraplegias1

Activity Timeline